Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 评价莽吉柿胶囊治疗原发性高脂血症的有效性和安全性的随机、双盲、剂量探索、安慰剂平行对照、多中心Ⅱ期临床研究
[Translation] A randomized, double-blind, dose-finding, placebo-controlled, multicenter phase II clinical study to evaluate the efficacy and safety of Mangjishi capsule in the treatment of primary hyperlipidemia
通过安慰剂对照探索莽吉柿胶囊治疗原发性高脂血症的有效剂量,并初步评价莽吉柿胶囊治疗原发性高脂血症的有效性和安全性 。
[Translation] To explore the effective dose of Mangosteen Capsules for the treatment of primary hyperlipidemia through placebo control, and preliminarily evaluate the efficacy and safety of Mangosteen Capsules in the treatment of primary hyperlipidemia.
莽吉柿胶囊治疗高脂血症随机、双盲、剂量平行对照多中心临床试验
[Translation] A randomized, double-blind, dose-controlled, multicenter clinical trial of Mangjishi capsules in the treatment of hyperlipidemia
1.通过探索性试验,明确莽吉柿胶囊治疗高脂血症的作用特点;
2.采用剂量对照,初步探索剂量与疗效的关系,为下一阶段临床试验提供依据。
[Translation] 1. Through exploratory trials, clarify the characteristics of the effect of Mangostana Capsules in treating hyperlipidemia;
2. Using dose control, preliminarily explore the relationship between dose and efficacy, and provide a basis for the next stage of clinical trials.
100 Clinical Results associated with Jilin Jianbang Pharmaceutical Technology Development Co., Ltd.
0 Patents (Medical) associated with Jilin Jianbang Pharmaceutical Technology Development Co., Ltd.
100 Deals associated with Jilin Jianbang Pharmaceutical Technology Development Co., Ltd.
100 Translational Medicine associated with Jilin Jianbang Pharmaceutical Technology Development Co., Ltd.